CGT-4255

N/A

Report date: 2026/01/27 20:00:10
NME

Base Information

Drug NameCGT-4255
Drug Alias NameCGT4255CGT-4255
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCogent Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesCogent Biosciences Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A